Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

DeepDyve requires Javascript to function. Please enable Javascript on your browser to continue.

Melanoma Research

Subject Areas: Cancer Research; ; ;
Publisher: Wolters Kluwer - Wolters Kluwer Health
ISSN: 1473-5636
SJR: 75

Open Access

Journal Article

Targeting beta-adrenergic receptor pathways in melanoma: how stress modulates oncogenic immunity

Switzer, Benjamin; Puzanov, Igor; Gandhi, Shipra; Repasky, Elizabeth A.

2024 Melanoma Research

doi:10.1097/cmr.0000000000000943 pmid:38051781

The intricate pathways of the sympathetic nervous system hold an inherently protective role in the setting of acute stress. This is achieved through dynamic immunomodulatory and neurobiological networks. However, excessive and chronic exposure to these stress-induced stimuli appears to cause...
Open Access

Journal Article

The role of artificial intelligence and convolutional neural networks in the management of melanoma: a clinical, pathological, and radiological perspective

Yee, Joshua; Rosendahl, Cliff; Aoude, Lauren G.

2024 Melanoma Research

doi:10.1097/cmr.0000000000000951 pmid:38141179

Clinical dermatoscopy and pathological slide assessment are essential in the diagnosis and management of patients with cutaneous melanoma. For those presenting with stage IIC disease and beyond, radiological investigations are often considered. The dermatoscopic, whole slide and radiological...
LitStream

Journal Article

The effect of microRNA-9 overexpression on inhibition of melanoma cancer stem cells tumorigenicity

Parisa, Sahranavardfard; Amirhossein, Izadpanah; Hamed, Yasavoli-Sharahi; Javad, Firouzi; Masoumeh, Azimi; Pardis, Khosravani; Mahshad, Dorraj; Faezeh, Keighobadi; Marzieh, Ebrahimi

2024 Melanoma Research

doi:10.1097/cmr.0000000000000931 pmid:38224358

Most of the studies have reported the downregulation of miR-9 in metastatic melanomas compared to primary tumors. They indicated that miR-9 negatively regulates the epithelial-to-mesenchymal transition (EMT) by inhibiting SNAIL1 expression and consequently promotes CDH1 expression. Since the...
LitStream

Journal Article

Hypoxic transcriptomes predict survival and tumor-infiltrating immune cell composition in cutaneous melanoma

Diaz, Michael J.; Quach, Jessica; Song, Joanna; Milanovic, Silvija; Tran, Jasmine T.; Ladehoff, Lauren C.; Batchu, Sai; Whitman, Patrick; Kaffenberger, Benajmin H.; Montanez-Wiscovich, Marjorie E.

2024 Melanoma Research

doi:10.1097/cmr.0000000000000938 pmid:38329217

Hypoxia has established associations with aggressive tumor phenotypes in many cancers. However, it is not currently understood whether tumor hypoxia levels map to distinct immune infiltrates in cutaneous melanoma, potentially unveiling novel therapeutic targets. To this end, we leveraged a...
Open Access

Journal Article

Clinical and genetic determinants of vitamin D receptor expression in cutaneous melanoma patients

De Smedt, Julie; Aura, Claudia; Van Kelst, Sofie; Janssen, Laudine; Marasigan, Vivien; Boecxstaens, Veerle; Stas, Marguerite; Bogaerts, Kris; Belmans, Ann; Cleynen, Isabelle; Vanderschueren, Dirk; Vandenberghe, Katleen; Bechter, Oliver; Nikkels, Arjen; Strobbe, Tinne; Emri, Gabriella; Lambrechts, Dieter; Garmyn, Marjan

2024 Melanoma Research

doi:10.1097/cmr.0000000000000929 pmid:38348498

Decrease of vitamin D receptor (VDR) expression is observed in melanocytic naevi and melanoma compared to normal skin. Little is known about factors influencing VDR expression in cutaneous melanoma (CM). We investigated the correlation of VDR expression in CM with 25-hydroxy vitamin D (25OHD)...
Open Access

Journal Article

Evaluating the efficacy of combination and single-agent immunotherapies in real-world patterns of disease progression and survival of metastatic melanoma patients

Ko, Brian; Tao, Kevin; Brennan, Lachlan; Rakhade, Swanand; Chan, Cynthia X.; Moone, Jee-Young; Zhu, Richard; Sher, Ariel; Wang, Samuel; Bracero, Yadriel; Fullerton, Ben; McLellan, Beth; Geskin, Larisa J.; Saenger, Yvonne M.

2024 Melanoma Research

doi:10.1097/cmr.0000000000000945 pmid:38181115

The objective of this study is to describe survival outcomes in patients with metastatic melanoma in a real-world setting receiving combination and single-agent immunotherapy outside the clinical trial context. We conducted a retrospective single-institution study of patients with metastatic...
Open Access

Journal Article

Dabrafenib plus trametinib in unselected advanced BRAF V600–mut melanoma: a non-interventional, multicenter, prospective trial

Richtig, Erika; Nguyen, Van A.; Koelblinger, Peter; Wolf, Ingrid; Kehrer, Helmut; Saxinger, Werner; Ressler, Julia M.; Weinlich, Georg; Meyersburg, Damian; Hafner, Christine; Jecel-Grill, Elisabeth; Kofler, Julian; Lange-Asschenfeldt, Bernhard; Weihsengruber, Felix; Rappersberger, Klemens; Svastics, Nina; Gasser, Klaus; Seeber, Arno; Kratochvill, Franz; Nagler, Sophie; Mraz, Bernhard; Hoeller, Christoph

2024 Melanoma Research

doi:10.1097/cmr.0000000000000948 pmid:38092013

Objective The efficacy of combined BRAF and MEK inhibition for BRAF V600–mutant melanoma in a broad patient population, including subgroups excluded from phase 3 trials, remains unanswered. This noninterventional study (DATUM-NIS) assessed the real-world efficacy, safety and tolerability of...
Open Access

Journal Article

Real-world management practices and characteristics of patients with advanced melanoma initiated on immuno-oncology or targeted therapy in the first-line setting during the period 2015–2018 in Greece. The ‘SUMMER’ study: a retrospective multicenter chart review project

Bafaloukos, Dimitrios; Kouzis, Panagiotis; Gouveris, Panagiotis; Boukovinas, Ioannis; Kalbakis, Konstantinos; Baka, Sofia; Kyriakakis, Georgios; Moschou, Despoina; Molfeta, Aristea; Demiri, Stamatia; Mavroudis, Dimitrios; Spanoudi, Filio; Dimitriadis, Ioannis; Gogas, Helen

2024 Melanoma Research

doi:10.1097/cmr.0000000000000949 pmid:38092014

This study primarily aimed to generate real-world evidence (RWE) on the profile and first-line treatment (1LT) patterns of patients with advanced (unresectable Stage III/metastatic) cutaneous melanoma initiated on immuno-oncology (IO)- or targeted therapy (TT)-based 1LT between 1 January 2015...
Open Access

Journal Article

Patterns of radiological response to tebentafusp in patients with metastatic uveal melanoma

Roshardt Prieto, Natalia M.; Turko, Patrick; Zellweger, Caroline; Nguyen-Kim, Thi Dan Linh; Staeger, Ramon; Bellini, Elisa; Levesque, Mitchell P.; Dummer, Reinhard; Ramelyte, Egle

2024 Melanoma Research

doi:10.1097/cmr.0000000000000952 pmid:38126339

Metastatic uveal melanoma (mUM) is a rare type of melanoma with poor outcomes. The first systemic treatment to significantly prolong overall survival (OS) in patients with mUM was tebentafusp, a bispecific protein that can redirect T-cells to gp-100 positive cells. However, the objective...
Open Access

Journal Article

Pregnancy-associated melanoma: characteristics and outcomes from 2002 to 2020

Davidson, Tara M.; Hieken, Tina J.; Glasgow, Amy E.; Habermann, Elizabeth B.; Yan, Yiyi

2024 Melanoma Research

doi:10.1097/cmr.0000000000000953 pmid:38265469

Melanoma diagnosed within 1 year of pregnancy is defined as pregnancy-associated melanoma (PAM). No robust data on how pregnancy influences melanoma nor guidelines for PAM management exist. With IRB approval, female patients with a pathology-confirmed melanoma diagnosis within 1 year of...

results per page

Prev
1
2
Next